S&P 500   4,449.73 (+0.02%)
DOW   34,768.32 (+0.01%)
QQQ   371.17 (-0.49%)
AAPL   146.06 (-0.52%)
MSFT   297.29 (-0.76%)
FB   348.59 (+0.76%)
GOOGL   2,832.87 (+0.30%)
TSLA   761.30 (+1.02%)
AMZN   3,399.44 (-0.48%)
NVDA   218.98 (-2.60%)
BABA   146.34 (-3.21%)
NIO   35.51 (-1.39%)
CGC   13.98 (-3.98%)
GE   104.00 (+1.01%)
MU   74.30 (+0.35%)
AMD   105.12 (-0.97%)
T   27.17 (-0.07%)
F   13.84 (+0.95%)
ACB   6.01 (-2.28%)
DIS   175.56 (-0.39%)
PFE   43.93 (-0.59%)
BA   221.16 (+0.03%)
BAC   42.22 (+1.27%)
S&P 500   4,449.73 (+0.02%)
DOW   34,768.32 (+0.01%)
QQQ   371.17 (-0.49%)
AAPL   146.06 (-0.52%)
MSFT   297.29 (-0.76%)
FB   348.59 (+0.76%)
GOOGL   2,832.87 (+0.30%)
TSLA   761.30 (+1.02%)
AMZN   3,399.44 (-0.48%)
NVDA   218.98 (-2.60%)
BABA   146.34 (-3.21%)
NIO   35.51 (-1.39%)
CGC   13.98 (-3.98%)
GE   104.00 (+1.01%)
MU   74.30 (+0.35%)
AMD   105.12 (-0.97%)
T   27.17 (-0.07%)
F   13.84 (+0.95%)
ACB   6.01 (-2.28%)
DIS   175.56 (-0.39%)
PFE   43.93 (-0.59%)
BA   221.16 (+0.03%)
BAC   42.22 (+1.27%)
S&P 500   4,449.73 (+0.02%)
DOW   34,768.32 (+0.01%)
QQQ   371.17 (-0.49%)
AAPL   146.06 (-0.52%)
MSFT   297.29 (-0.76%)
FB   348.59 (+0.76%)
GOOGL   2,832.87 (+0.30%)
TSLA   761.30 (+1.02%)
AMZN   3,399.44 (-0.48%)
NVDA   218.98 (-2.60%)
BABA   146.34 (-3.21%)
NIO   35.51 (-1.39%)
CGC   13.98 (-3.98%)
GE   104.00 (+1.01%)
MU   74.30 (+0.35%)
AMD   105.12 (-0.97%)
T   27.17 (-0.07%)
F   13.84 (+0.95%)
ACB   6.01 (-2.28%)
DIS   175.56 (-0.39%)
PFE   43.93 (-0.59%)
BA   221.16 (+0.03%)
BAC   42.22 (+1.27%)
S&P 500   4,449.73 (+0.02%)
DOW   34,768.32 (+0.01%)
QQQ   371.17 (-0.49%)
AAPL   146.06 (-0.52%)
MSFT   297.29 (-0.76%)
FB   348.59 (+0.76%)
GOOGL   2,832.87 (+0.30%)
TSLA   761.30 (+1.02%)
AMZN   3,399.44 (-0.48%)
NVDA   218.98 (-2.60%)
BABA   146.34 (-3.21%)
NIO   35.51 (-1.39%)
CGC   13.98 (-3.98%)
GE   104.00 (+1.01%)
MU   74.30 (+0.35%)
AMD   105.12 (-0.97%)
T   27.17 (-0.07%)
F   13.84 (+0.95%)
ACB   6.01 (-2.28%)
DIS   175.56 (-0.39%)
PFE   43.93 (-0.59%)
BA   221.16 (+0.03%)
BAC   42.22 (+1.27%)
NYSE:SQZ

SQZ Biotechnologies Stock Forecast, Price & News

$14.98
-0.26 (-1.71 %)
(As of 09/24/2021 11:08 AM ET)
Add
Compare
Today's Range
$14.98
$15.16
50-Day Range
$11.46
$15.24
52-Week Range
$11.15
$36.49
Volume144 shs
Average Volume166,828 shs
Market Capitalization$420.14 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
30 days | 90 days | 365 days | Advanced Chart
Receive SQZ News and Ratings via Email

Sign-up to receive the latest news and ratings for SQZ Biotechnologies and its competitors with MarketBeat's FREE daily newsletter.


SQZ Biotechnologies logo

About SQZ Biotechnologies

SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops transformative cell therapies for patients with cancer, infectious diseases, and other serious conditions. Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with other immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical, head-and-neck, anal, penile, vulvar, and vaginal cancer. The company also develops SQZ-AAC-HPV, which is in a Phase I clinical trial for the treatment of HPV16+ advanced or metastatic solid tumors in monotherapy and in combinations with other immune-oncology agents. Its additional platforms in development are SQZ Activating Antigen Carriers; and SQZ Tolerizing Antigen Carriers. SQZ Biotechnologies Company was incorporated in 2013 and is headquartered in Watertown, Massachusetts.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

2.03 out of 5 stars

Medical Sector

532nd out of 1,351 stocks

Biological Products, Except Diagnostic Industry

83rd out of 193 stocks

Analyst Opinion: 3.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











SQZ Biotechnologies (NYSE:SQZ) Frequently Asked Questions

Is SQZ Biotechnologies a buy right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for SQZ Biotechnologies in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" SQZ Biotechnologies stock.
View analyst ratings for SQZ Biotechnologies
or view top-rated stocks.

What stocks does MarketBeat like better than SQZ Biotechnologies?

Wall Street analysts have given SQZ Biotechnologies a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but SQZ Biotechnologies wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting SQZ Biotechnologies?

SQZ Biotechnologies saw a decline in short interest during the month of August. As of August 31st, there was short interest totaling 1,230,000 shares, a decline of 20.1% from the August 15th total of 1,540,000 shares. Based on an average daily volume of 174,200 shares, the short-interest ratio is presently 7.1 days. Approximately 6.5% of the shares of the stock are short sold.
View SQZ Biotechnologies' Short Interest
.

When is SQZ Biotechnologies' next earnings date?

SQZ Biotechnologies is scheduled to release its next quarterly earnings announcement on Thursday, December 9th 2021.
View our earnings forecast for SQZ Biotechnologies
.

How were SQZ Biotechnologies' earnings last quarter?

SQZ Biotechnologies (NYSE:SQZ) issued its quarterly earnings data on Tuesday, August, 3rd. The company reported ($0.68) EPS for the quarter, missing analysts' consensus estimates of ($0.57) by $0.11. The company had revenue of $4.54 million for the quarter, compared to analyst estimates of $6.24 million. SQZ Biotechnologies had a negative trailing twelve-month return on equity of 74.70% and a negative net margin of 346.39%.
View SQZ Biotechnologies' earnings history
.

What price target have analysts set for SQZ?

5 equities research analysts have issued 12 month target prices for SQZ Biotechnologies' stock. Their forecasts range from $37.00 to $40.00. On average, they expect SQZ Biotechnologies' share price to reach $38.33 in the next twelve months. This suggests a possible upside of 155.9% from the stock's current price.
View analysts' price targets for SQZ Biotechnologies
or view top-rated stocks among Wall Street analysts.

Who are SQZ Biotechnologies' key executives?

SQZ Biotechnologies' management team includes the following people:
  • Dr. Armon R. Sharei, Co-Founder, Pres, CEO & Director (Age 34, Pay $692.57k)
  • Ms. Teri Loxam, Chief Financial Officer (Age 49, Pay $633.03k)
  • Mr. Lawrence J. Knopf, Gen. Counsel & Sec. (Age 59, Pay $474.45k)
  • Dr. Oliver Rosen, Chief Medical Officer (Age 57, Pay $557.29k)
  • Mr. Micah Zajic, Chief Bus. Officer (Age 40, Pay $288.65k)
  • Dr. Robert S. Langer Jr., Co-Founder & Member of Scientific Advisory Board (Age 72)
  • Dr. Howard Bernstein, Chief Scientific Officer (Age 64)
  • Mr. David First, Chief People Officer (Age 57)

When did SQZ Biotechnologies IPO?

(SQZ) raised $75 million in an initial public offering on Friday, October 30th 2020. The company issued 4,400,000 shares at $16.00-$18.00 per share. BofA Securities and Stifel acted as the underwriters for the IPO and BTIG was co-manager.

What is SQZ Biotechnologies' stock symbol?

SQZ Biotechnologies trades on the New York Stock Exchange (NYSE) under the ticker symbol "SQZ."

Who are SQZ Biotechnologies' major shareholders?

SQZ Biotechnologies' stock is owned by a number of retail and institutional investors. Top institutional investors include 683 Capital Management LLC (4.90%), BlackRock Inc. (4.34%), Maverick Capital Ltd. (3.51%), Vanguard Group Inc. (3.18%), State Street Corp (1.02%) and Geode Capital Management LLC (0.87%).

Which major investors are buying SQZ Biotechnologies stock?

SQZ stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., 683 Capital Management LLC, Vanguard Group Inc., State Street Corp, JPMorgan Chase & Co., Morgan Stanley, Morgan Stanley, and Geode Capital Management LLC.

How do I buy shares of SQZ Biotechnologies?

Shares of SQZ can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is SQZ Biotechnologies' stock price today?

One share of SQZ stock can currently be purchased for approximately $14.98.

How much money does SQZ Biotechnologies make?

SQZ Biotechnologies has a market capitalization of $420.14 million and generates $21 million in revenue each year. The company earns $-50,520,000.00 in net income (profit) each year or ($9.35) on an earnings per share basis.

How many employees does SQZ Biotechnologies have?

SQZ Biotechnologies employs 98 workers across the globe.

What is SQZ Biotechnologies' official website?

The official website for SQZ Biotechnologies is www.sqzbiotech.com.

Where are SQZ Biotechnologies' headquarters?

SQZ Biotechnologies is headquartered at 200 ARSENAL YARDS BLVD. STE. 210, WATERTOWN MA, 02472.

How can I contact SQZ Biotechnologies?

SQZ Biotechnologies' mailing address is 200 ARSENAL YARDS BLVD. STE. 210, WATERTOWN MA, 02472. The company can be reached via phone at 617-758-8672 or via email at [email protected].


This page was last updated on 9/24/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.